This HTML5 document contains 96 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/national-drug-code-directory/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/guide-to-pharmacology/
n27http://linked.opendata.cz/resource/AHFS/
n22http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/chebi/
n25http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/wikipedia/
n21http://www.rxlist.com/cgi/generic/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/kegg-compound/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01219/identifier/iuphar/
n24http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01219
rdf:type
n3:Drug
n3:description
Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
n3:dosage
n26:271B5882-363D-11E5-9242-09173F13E4C5 n26:271B5885-363D-11E5-9242-09173F13E4C5 n26:271B5883-363D-11E5-9242-09173F13E4C5 n26:271B5884-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15023108
n3:group
approved
n3:halfLife
The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.
n3:indication
For use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
owl:sameAs
n12:DB01219 n25:DB01219
dcterms:title
Dantrolene
adms:identifier
n7:4172 n8:4172 n9:DB01219 n10:27505-001-66 n13:C06939 n14:D02347 n15:4317 n18:PA449208 n19:Dantrolene
n3:mechanismOfAction
Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction.
n3:packager
n22:271B5875-363D-11E5-9242-09173F13E4C5 n22:271B5876-363D-11E5-9242-09173F13E4C5 n22:271B5873-363D-11E5-9242-09173F13E4C5 n22:271B5874-363D-11E5-9242-09173F13E4C5 n22:271B5871-363D-11E5-9242-09173F13E4C5 n22:271B5872-363D-11E5-9242-09173F13E4C5 n22:271B586F-363D-11E5-9242-09173F13E4C5 n22:271B5870-363D-11E5-9242-09173F13E4C5 n22:271B586D-363D-11E5-9242-09173F13E4C5 n22:271B586E-363D-11E5-9242-09173F13E4C5 n22:271B586C-363D-11E5-9242-09173F13E4C5
n3:synonym
Dantamacrin F-368 Dantrium Dantroleno Dantrolene SID26756773 Dantrolenum SID26756482
n3:toxicity
Oral LD<sub>50</sub> in rats is 7400 mg/kg. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.
n23:hasAHFSCode
n27:12-20-00
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
Significant, mostly to albumin.
n3:salt
n3:synthesisReference
Davis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to The Norwich Pharmacal Company.
n28:hasConcept
n29:M0005658
foaf:page
n17:dantrolene.html n21:dantrolene.htm
n3:IUPAC-Name
n4:271B588A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5890-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B588F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B588C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B588D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B588E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5888-363D-11E5-9242-09173F13E4C5 n4:271B58A0-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5886-363D-11E5-9242-09173F13E4C5 n4:271B58A2-363D-11E5-9242-09173F13E4C5 n4:271B5889-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5887-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n24:M03CA01
n3:H-Bond-Acceptor-Count
n4:271B5896-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5897-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5891-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5892-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5894-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5893-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5895-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is 70%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7261-97-4
n3:category
n3:containedIn
n5:271B587D-363D-11E5-9242-09173F13E4C5 n5:271B587B-363D-11E5-9242-09173F13E4C5 n5:271B587C-363D-11E5-9242-09173F13E4C5 n5:271B587E-363D-11E5-9242-09173F13E4C5 n5:271B587F-363D-11E5-9242-09173F13E4C5 n5:271B5880-363D-11E5-9242-09173F13E4C5 n5:271B5881-363D-11E5-9242-09173F13E4C5 n5:271B5879-363D-11E5-9242-09173F13E4C5 n5:271B587A-363D-11E5-9242-09173F13E4C5 n5:271B5877-363D-11E5-9242-09173F13E4C5 n5:271B5878-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B589C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B589E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B589F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B58A1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B589B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B589A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B589D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B588B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5898-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5899-363D-11E5-9242-09173F13E4C5